Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
+44 1478 350008
ISSN: 2329-8790
+44 1478 350008
Susie L. Ponce
Philippines
Research Article
Descriptive, Comparative Study of Filipino Myelofibrosis Patients: An Agematched Comparison of Patients on Ruxolitinib vs. Best Available Therapy
Author(s): Flordeluna Zapata-Mesina, Ma Rosario Irene D. Castillo, Priscilla B. Caguioa, Honorata G. Baylon, Narcisa Sonia C. Comia, Catherine C. Rosales and Susie L. PonceFlordeluna Zapata-Mesina, Ma Rosario Irene D. Castillo, Priscilla B. Caguioa, Honorata G. Baylon, Narcisa Sonia C. Comia, Catherine C. Rosales and Susie L. Ponce
Introduction: Myelofibrosis is characterized by bone marrow fibrosis, cytopenias and extramedullary hematopoiesis. Ruxolitinib is a Janus Kinase-2 inhibitor recently approved for myelofibrosis. In the Philippines, it was made available through the compassionate use program.
Methods: This is a multicentre, retrospective case series of eleven patients in the compassionate use program and eleven age-matched historical controls on best available therapy.
Results: The median age was 54.5+7.33, 82% females. Using the International Working Group on Myelofibrosis Research and Treatment (IWG-MRT) consensus criteria of 2013, 1 out of the 11 patients had both spleen response and anemia response, achieving transfusion independence for > 12 weeks. Nine patients experienced clinical improvement specifically spleen response. D.. View More»
DOI:
10.4172/2329-8790.1000178